38 related articles for article (PubMed ID: 29305520)
21. Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions.
Hajaj E; Zisman E; Tzaban S; Merims S; Cohen J; Klein S; Frankenburg S; Sade-Feldman M; Tabach Y; Yizhak K; Navon A; Stepensky P; Hacohen N; Peretz T; Veillette A; Karni R; Eisenberg G; Lotem M
Cancer Immunol Res; 2021 Jun; 9(6):637-650. PubMed ID: 33762352
[TBL] [Abstract][Full Text] [Related]
22. SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint.
Hajaj E; Eisenberg G; Klein S; Frankenburg S; Merims S; Ben David I; Eisenhaure T; Henrickson SE; Villani AC; Hacohen N; Abudi N; Abramovich R; Cohen JE; Peretz T; Veillette A; Lotem M
Elife; 2020 Mar; 9():. PubMed ID: 32122464
[TBL] [Abstract][Full Text] [Related]
23. SLAMF6 as a Regulator of Exhausted CD8
Yigit B; Wang N; Ten Hacken E; Chen SS; Bhan AK; Suarez-Fueyo A; Katsuyama E; Tsokos GC; Chiorazzi N; Wu CJ; Burger JA; Herzog RW; Engel P; Terhorst C
Cancer Immunol Res; 2019 Sep; 7(9):1485-1496. PubMed ID: 31315913
[TBL] [Abstract][Full Text] [Related]
24. SLAMF6 clustering is required to augment T cell activation.
Dragovich MA; Adam K; Strazza M; Tocheva AS; Peled M; Mor A
PLoS One; 2019; 14(6):e0218109. PubMed ID: 31199820
[TBL] [Abstract][Full Text] [Related]
25. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.
Contreras A; Sen S; Tatar AJ; Mahvi DA; Meyers JV; Srinand P; Suresh M; Cho CS
Cancer Immunol Immunother; 2016 May; 65(5):601-11. PubMed ID: 27011014
[TBL] [Abstract][Full Text] [Related]
26. Soluble SLAMF6 Receptor Induces Strong CD8
Eisenberg G; Engelstein R; Geiger-Maor A; Hajaj E; Merims S; Frankenburg S; Uzana R; Rutenberg A; Machlenkin A; Frei G; Peretz T; Lotem M
Cancer Immunol Res; 2018 Feb; 6(2):127-138. PubMed ID: 29305520
[TBL] [Abstract][Full Text] [Related]
27. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
28. SLAMF6 in health and disease: Implications for therapeutic targeting.
Yigit B; Wang N; Herzog RW; Terhorst C
Clin Immunol; 2019 Jul; 204():3-13. PubMed ID: 30366106
[No Abstract] [Full Text] [Related]
29. Preclinical studies, experimental therapeutics, and clinical management of advanced melanoma.
Kirkwood JM
Curr Opin Oncol; 1992 Apr; 4(2):368-79. PubMed ID: 1591310
[TBL] [Abstract][Full Text] [Related]
30.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
31.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
32.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]